Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695615 | 0.88 | CA12 (0.47) | MAPTALDH1A1LMNANPSR1HTT | |
| SCHEMBL6934835 | 0.86 | MEN1 (0.57) | MAPTALDH1A1LMNANPSR1HTT | |
| SCHEMBL6934839 | 0.86 | MEN1 (0.57) | MAPTALDH1A1LMNANPSR1HTT | |
| SCHEMBL1695618 | 0.85 | ALDH1A1 (0.47) | MAPTALDH1A1LMNANPSR1HTT | |
| SCHEMBL5216896 | 0.85 | SMN1; SMN2 (0.49) | MAPTALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL5216893 | 0.85 | SMN1; SMN2 (0.49) | MAPTALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL14565691 | 0.85 | SMN1; SMN2 (0.49) | MAPTALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL15389739 | 0.80 | SMN1; SMN2 (0.49) | MAPTALDH1A1LMNANPSR1HPGD | |
| SCHEMBL15389738 | 0.80 | SMN1; SMN2 (0.49) | MAPTALDH1A1LMNANPSR1HPGD | |
| SCHEMBL5221257 | 0.79 | ALDH1A1 (0.46) | MAPTALDH1A1LMNANPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062401-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | NEUMORA THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4626878-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12371414-B2 | Methods of treating neurological disorders | Neumora Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240294492-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. | 2024-09-05 | — | — | US | disclosed |
| US-20240246928-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. | 2024-07-25 | — | — | US | disclosed |
| WO-2024119067-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024119067-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-11993580-B1 | Methods of treating neurological disorders | Neumora Therapeutics, Inc. (US) | 2024-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993580-B1 | Methods of treating neurological disorders | SMN1; SMN2, CLN6, PMP22 | MAPT 96/4885ALDH1A1 425/4885LMNA 1483/4885 |
| US-20240246928-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | SMN1; SMN2, CLN6, PMP22 | MAPT 96/4885ALDH1A1 425/4885LMNA 1483/4885 |
| US-20260062401-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | HCN2, HCN3, HCN1 | MAPT 391/4885ALDH1A1 1440/4885LMNA 522/4885 |
| US-20240294492-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | SMN1; SMN2, CLN6, PMP22 | MAPT 101/4885ALDH1A1 414/4885LMNA 1536/4885 |
| US-12371414-B2 | Methods of treating neurological disorders | SMN1; SMN2, CLN6, PMP22 | MAPT 96/4885ALDH1A1 425/4885LMNA 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.